, showing deposition of fibrillin-1 (Fibr-1; B/W, red) and FN (B/W, green), with nuclei stained with DAPI (blue). Images were taken using a 20× objective. Specific band-pass filter sets for DAPI, FITC, and Cy3 or Cy5 were used to prevent bleedthrough. Control cultures (Con) showed partial colocalisation of fibrillin-1 and FN (yellow). FN knockdown (kd) HDF cultures had no detectable microfibrils. EXT1 knockdown (kd) HDFs had disordered microfibrils but no apparent FN changes. Scale bars = 100 μm. n = 2 (B) Fibrillin-1 deposition was quantified using ImageJ. The percentage area was calculated by applying an equal threshold value over all the images and measuring the area of the brightest pixels corresponding to fibrillin fibrils. For each cell type, at least 3 images were used and the graph shows the mean percentage area and SEM. Statistical significance for deviation from the control cellline values was calculated using a 2-way ANOVA with a Bonferroni's multiple comparisons test using GraphPad Prism V6. Asterisk indicate P values where *** = P ≤ 0.001. (C) Medium and cell layer extracts from HDF cells in control (Con) and knockdown (kd) experiments (perlecan, EXT1, PKCα, FN, syndecan-2 or syndecan-4) were separated on 3-8% Tris-acetate gels in reducing conditions, and analyzed by western blotting for fibrillin-1 (antibody HPA021057) or FN (antibody FN-3E2 ), or β-actin (mAbAC-74) as loading control for cell layer extracts. Molecular weight markers are indicated. Quantification of band intensity is shown as a percentage of control band intensity (where Con = 100%). Data shown are from a single representative experiment, with biological and technical repeats exhibiting the same trends (n = 3).
Fig. S2. Relative expression levels in ARPE-19A and B cells, podocytes, and human dermal fibroblasts (HDFs). (A)
Realtime quantitative PCR (qPCR) analysis of gene expression of fibrillin-1 (Fibr-1), fibronectin (FN), EXT1, perlecan (Perl), PKCα and syndecans (Syn) 1-4 in (i) (ii) (iii) podocyte (all 7 days) and (iv) HDF cultures (4 days). (B) Real-time qPCR analysis of gene expression of E-cadherin (E-cad), N-cadherin (N-cad), PDGF receptor-β (PDGFRβ), smooth muscle α-actin (SMA), SNAI1, SNAI2 and TWIST 1 in (i) (ii) and (iii) podocyte cultures (all 7 days). For both (A) and (B), expression is reported relative to TATA box binding protein (TBP) , where TBP expression is equal to 1. Data are represented as the mean ± s.e.m. See Table S1 for details of n values for ARPE-19A and B cultures; for podocytes, n = 3; for HDF in (A) (iii), n = 6-12, depending on gene. (FN) , syndecans (Syn) 1-4, E-cadherin (E-cad), N-cadherin (N-cad), PDGF receptor-β (PDGFRβ), smooth muscle α-actin (SMA), SNAI1, SNAI2 and TWIST 1 following knockdown of FN in podocyte cultures (7 days). Samples were either normalised to a combination of GAPDH/TBP expression (A, B and D), or to TBP expression (C) prior to being reported as fold changes relative to lipofectamine-treated control cell expression of either ARPE-19A, ARPE-19B, HDF or podocyte accordingly (where Con = 1). All data are represented as the mean ± s.e.m. and analyzed by 2-way ANOVA, with *P<0.05; **P<0.01; ***P<0.001. See Table S1 for details of n values for ARPE-19A and B cultures; for HDF, n = 3-16, depending on gene and knockdown condition. (E-H) qPCR analysis of expression levels of fibrillin-1 (Fibr-1), fibronectin (FN), EXT1, Perlecan (Perl), PKCα (PKCα) and syndecans (Syn) 1-4, following knockdown of syndecan-2, syndecan-4 or PKCα in (E) ARPE-19A, (F) ARPE-19B cells (both 7 days) and (G) HDF cultures (4 days). Samples were either normalised to a combination of GAPDH/TBP expression (E and F), or to TBP expression (G) prior to being reported as fold changes relative to lipofectamine-treated control cell expression of either ARPE-19A, ARPE-19B, or HDF accordingly (where Con = 1). All data are represented as mean ± s.e.m. and analyzed by 2-way ANOVA, with *P<0.05; **P<0.01; ***P<0.001. See Table S1 for details of n values for ARPE-19A and B cultures; for HDF, n = 3-16, depending on gene and knockdown condition. (H) Cell lysate samples of were separated on 4-12% Bis-Tris gels in reducing conditions, and analyzed by western blotting for PKCα or β-actin (mAbAC-74) as loading control for cell layer extracts. Molecular weight markers are indicated. Verification of PKCα kd was achieved via quantification of band intensity ("Expression"), shown as a percentage of control band intensity (where Con = 100%). . Boxed areas are shown as zoomed images on right. PKCα, syndecan-2 and syndecan-4 knockdown (kd) HDFs had few microfibrils but abundant FN. For both (A) and (B), images were taken using a 20× objective. Scale bars = 100 μm, n = 3. For all microscopy, specific band-pass filter sets for DAPI, FITC, and Cy3 or Cy5 were used to prevent bleed-through. Fig. S6 . Real-time quantitative PCR analysis of syndecan and E-cadherin expression levels following siRNA treatments. qPCR analysis of expression levels of (A) syndecans 1-4 and (B) E-cadherin, following knockdown of EXT1, FN, perlecan, PKCα, syndecan-2 or syndecan-4 in ARPE-19A cells (black bars) and ARPE-19B cells (white bars; both 7 days). Samples were normalised to a combination of GAPDH/TBP expression prior to being reported as fold changes relative to ARPE-19A lipofectamine-treated control cell expression (where ARPE-19A Con = 1). E-cadherin expression is lower in control ARPE-19B cultures compared to control ARPE-19A cultures (see also Fig. 2 ). In both ARPE-19A and B cells, knockdown of EXT1 results in an increase in E-cadherin expression. None of the other gene knockdowns tested changed E-cadherin expression in ARPE-19B cells, whereas knockdown of perlecan and PKCα had consequences for E-cadherin expression in ARPE-19A cells. (C) Real-time quantitative PCR (qPCR) analysis of gene expression of syndecans 1-4 in control (Con) and FN kd ARPE-19A and B cells. For (A), (B) and (C), the "Gene Study" functionality of CFX Manager was utilised. In order to use the "Gene Study" software throughout the experiment, datasets were generated for ARPE-19A and B cells (for (A) and (C), n = 3-5, and for (B) n = 3-9, depending on the knockdown condition). All data are represented as the mean ± s.e.m. and analyzed by 2-way ANOVA, with *P<0.05; **P<0.01; ***P<0.001. 
